Building a large collection of multimodal data in oncology
Multi Omics and Spatial Atlas In Cancer
This study is trying to gather a lot of different types of data about cancer to see if it can help find personalized treatments for people with diffuse large B cell lymphoma and solid tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Owkin |
| Drugs / interventions | immunotherapy |
| Locations | 5 sites (Pittsburgh, Pennsylvania and 4 other locations) |
| Trial ID | NCT06625203 on ClinicalTrials.gov |
What this trial studies
This study aims to create the largest collection of multimodal data, including clinical, imaging, and omics data, to enhance understanding of cancer biology and treatment strategies. By leveraging advances in artificial intelligence and next-generation sequencing, the research seeks to identify personalized treatment opportunities for patients with diffuse large B cell lymphoma and solid tumors. The study will collect data from multiple international centers, focusing on the tumor microenvironment and its role in cancer progression. Participants will provide informed consent and must have specific tissue samples available for analysis.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with a confirmed diagnosis of diffuse large B cell lymphoma or solid tumors who can provide the necessary tissue samples and clinical data.
Not a fit: Patients without the required tissue samples or those who do not meet the eligibility criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for cancer patients.
How similar studies have performed: Other studies utilizing multimodal data approaches in oncology have shown promise, indicating that this methodology is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. That the patient was over the age of 18 when the sample was taken/consented to. 2. Availability of patient informed consent or non-opposition form to perform exploratory research matching at least one of the MOSAIC objectives (unless authorisation is granted by the local Institutional Review Board / Independent Ethics Committee (IRB/IEC) for the use of samples in the study according to local regulations and law). 3. Have a confirmed diagnosis based on international criteria for the relevant tumor type. 4. Confirmed formalin fixed and paraffin embedded (FFPE) tissue availability to generate at least the 3 core data modalities, and preferentially all MOSAIC data modalities. 5. Confirmed availability of associated clinical data. 6. Qualification of the paraffin tissue block meeting all of the following: * Being of the expected tumor type * For solid tumors (all cancer indications except diffuse large B cell lymphoma (DLBCL)): Tumor cell content ranging from 40% to 80% on an hematoxylin and eosin (H\&E) section within a specified area as dictated by the lab protocol specific to the technique utilized * For DLBCL, a minimum of 80% of high grade component on an H\&E section within a specified area as dictated by the lab protocol specific to the technique utilized * Wherever possible, the remaining tissue thickness must be over 125 micrometers (indicative range) * Tumor sample must be \<10 years old In addition, each sub-cohort within each cancer indication will have specific inclusion criteria (e.g., disease stage; sampling site; treatment received…). Exclusion Criteria: 1\. Samples without a preserved tissue architecture, such as cytologies and cytoblocks. In addition, each sub-cohort within each cancer indication may have specific exclusion criteria (e.g. histological subtype; history of immunosuppression; etc…).
Where this trial is running
Pittsburgh, Pennsylvania and 4 other locations
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States (Recruiting)
- Gustave Roussy — Paris, France (Recruiting)
- Charité - Universitätsmedizin Berlin — Berlin, Germany (Recruiting)
- Universiy Hospital Erlangen & FAU Erlangen-Nürnberg — Erlangen, Germany (Recruiting)
- Centre Hospitalier Universitaire Vaudois — Lausanne, Switzerland (Recruiting)
Study contacts
- Study coordinator: Hubert Chaperon
- Email: hubert.chaperon@owkin.com
- Phone: +33 6 45 63 71 12
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.